These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21949845)

  • 61. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor.
    Sugita S; Kawashima H; Tanaka T; Kurisu T; Sugimura K; Nakatani T
    Oncol Rep; 2004 Jun; 11(6):1273-9. PubMed ID: 15138566
    [TBL] [Abstract][Full Text] [Related]  

  • 62. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.
    Yeh S; Lin HK; Kang HY; Thin TH; Lin MF; Chang C
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5458-63. PubMed ID: 10318905
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.
    Shiota M; Yokomizo A; Tada Y; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Fujimoto N; Seki N; Naito S
    Mol Endocrinol; 2010 Jan; 24(1):114-27. PubMed ID: 19884383
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Four and a half LIM domain 2 alters the impact of aryl hydrocarbon receptor on androgen receptor transcriptional activity.
    Kollara A; Brown TJ
    J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):51-8. PubMed ID: 19815066
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin.
    Li J; Fu J; Toumazou C; Yoon HG; Wong J
    Mol Endocrinol; 2006 Apr; 20(4):776-85. PubMed ID: 16373397
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone.
    Culig Z; Stober J; Gast A; Peterziel H; Hobisch A; Radmayr C; Hittmair A; Bartsch G; Cato AC; Klocker H
    Cancer Detect Prev; 1996; 20(1):68-75. PubMed ID: 8907206
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells.
    Mayeur GL; Kung WJ; Martinez A; Izumiya C; Chen DJ; Kung HJ
    J Biol Chem; 2005 Mar; 280(11):10827-33. PubMed ID: 15640154
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB.
    Trtkova K; Paskova L; Matijescukova N; Strnad M; Kolar Z
    Neoplasma; 2010; 57(5):406-14. PubMed ID: 20568894
    [TBL] [Abstract][Full Text] [Related]  

  • 69. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
    Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
    Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
    Lyons LS; Burnstein KL
    Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells.
    Gross M; Liu B; Tan J; French FS; Carey M; Shuai K
    Oncogene; 2001 Jun; 20(29):3880-7. PubMed ID: 11439351
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
    Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H
    Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
    Yoon HG; Wong J
    Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sterol regulatory element-binding protein-1c represses the transactivation of androgen receptor and androgen-dependent growth of prostatic cells.
    Suh JH; Gong EY; Kim JB; Lee IK; Choi HS; Lee K
    Mol Cancer Res; 2008 Feb; 6(2):314-24. PubMed ID: 18245227
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines.
    Beilin J; Ball EM; Favaloro JM; Zajac JD
    J Mol Endocrinol; 2000 Aug; 25(1):85-96. PubMed ID: 10915221
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
    Jia L; Kim J; Shen H; Clark PE; Tilley WD; Coetzee GA
    Mol Cancer Res; 2003 Mar; 1(5):385-92. PubMed ID: 12651911
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Modulation of androgen receptor transactivation by FoxH1. A newly identified androgen receptor corepressor.
    Chen G; Nomura M; Morinaga H; Matsubara E; Okabe T; Goto K; Yanase T; Zheng H; Lu J; Nawata H
    J Biol Chem; 2005 Oct; 280(43):36355-63. PubMed ID: 16120611
    [TBL] [Abstract][Full Text] [Related]  

  • 78. c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer.
    Cai C; Hsieh CL; Shemshedini L
    Mol Cancer Res; 2007 Jul; 5(7):725-35. PubMed ID: 17634427
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
    Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
    J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
    [TBL] [Abstract][Full Text] [Related]  

  • 80. FUS/TLS is a co-activator of androgen receptor in prostate cancer cells.
    Haile S; Lal A; Myung JK; Sadar MD
    PLoS One; 2011; 6(9):e24197. PubMed ID: 21909421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.